NDA 022041 · Btg Intl
Cyanokit
Hydroxocobalamin · Injection · Antidote
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Dec 31, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Dec 15, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
294
72 Phase 3, 20 recruiting
FAERS reports
4,238
3,876 serious, 315 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 27, 2023.
CYANOKIT is indicated for the treatment of known or suspected cyanide poisoning. CYANOKIT is indicated for the treatment of known or suspected cyanide poisoning. ( 1 )
Mechanism: Cyanide is an extremely toxic poison. In the absence of rapid and adequate treatment, exposure to a high dose of cyanide can result in death within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a3, a component of the cytochrome c oxidase complex in mitochondria. Inhibition of cytochrome a3 prevents the cell from using oxygen and forces anaerobic metabolism, resulting in lactate production, cellular hypoxia and metabolic acidosis. In massive acute cyanide poisoning, the mechanism of toxicity...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- CYANOKIT · HYDROXOCOBALAMIN 5GM/VIAL (5GM/KIT) · INJECTABLE, INJECTION · Prescription
- CYANOKIT · HYDROXOCOBALAMIN 2.5GM/VIAL (5GM/KIT) · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydroxocobalamin" as an intervention, any sponsor and status, largest first.
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04353180 · 100,000 participants (planned) · Start Aug 2021 · Primary completion Oct 2021
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment; Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment and 3 more · For: COVID19
Sites: Cairo, Egypt · 2 sites in all
- Study of the Effectiveness of Additional Reductions in Cholesterol and HomocysteinePivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00124072 · 12,064 participants · Start Jul 1998 · Primary completion May 2008
Drug: Simvastatin 20 mg daily; Simvastatin 80 mg daily and 1 more · For: Cardiovascular Disease
Sites: Oxford, United Kingdom
- VITATOPS: A Study of VITAmins TO Prevent StrokePivotal-lookingCompleted
VITATOPSGovernment (non-federal)
NCT00097669 · 8,164 participants · Start Nov 1998 · Primary completion Jun 2009
Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo · For: Stroke; Transient Ischemic Attack
Sites: New York, New York; Abington, Pennsylvania; Columbia, South Carolina · 111 sites in all
- HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)Pivotal-lookingStatus unknown
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT00106886 · 5,000 participants · Start Dec 1999
Drug: Folic acid, vitamin B6 and B12 or placebo · For: Cardiovascular Disease; Myocardial Infarction; Stroke and 1 more
Sites: Hamilton, Canada
- Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)Pivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00064753 · 4,110 participants · Start May 2002 · Primary completion Oct 2011
Drug: High Dose Multivitamin · For: Chronic Kidney Disease; Cardiovascular Disease; Death
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 30 sites in all
- The Norwegian Vitamin Trial (NORVIT)Pivotal-lookingCompleted
University of TromsoAcademic, hospital or other
NCT00266487 · 3,750 participants · Start Dec 1998
Drug: Folic acid; Vitamin B12 and 1 more · For: Acute Myocardial Infarction
Sites: Tromsø, Norway
- WENBIT - Western Norway B Vitamin Intervention TrialPivotal-lookingCompleted
Haukeland University HospitalAcademic, hospital or other
NCT00354081 · 3,096 participants · Start Apr 1999 · Primary completion Jun 2007
Drug: folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine); folic acid, vitamin B12 (cyanocobalamin) and 2 more · For: Coronary Artery Disease; Myocardial Infarction; Cerebrovascular Stroke
Sites: Bergen, Norway; Stavanger, Norway
- A Trial of Zinc and Micronutrients in Tanzanian ChildrenPivotal-lookingCompleted
Harvard School of Public Health (HSPH)Academic, hospital or other
NCT00421668 · 2,400 participants · Start Sep 2007 · Primary completion Oct 2012
Drug: Zinc; Multivitamins and 1 more · For: Diarrheal Illnesses; Respiratory Illness; Growth Faltering
Sites: Dar es Salaam, Tanzania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- acute kidney injury211
- nausea207
- diarrhoea205
- dyspnoea190
- dizziness178
- vomiting167
- off label use166
- malaise151
- hyponatraemia138
- fatigue136
- confusional state129
- rash120
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 9 |
| 2006 | 11 |
| 2007 | 19 |
| 2008 | 42 |
| 2009 | 32 |
| 2010 | 32 |
| 2011 | 77 |
| 2012 | 85 |
| 2013 | 98 |
| 2014 | 149 |
| 2015 | 152 |
| 2016 | 218 |
| 2017 | 252 |
| 2018 | 346 |
| 2019 | 393 |
| 2020 | 377 |
| 2021 | 278 |
| 2022 | 320 |
| 2023 | 350 |
| 2024 | 368 |
| 2025 | 305 |
| 2026 | 319 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 16, 2026
Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11). Other
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Hydroxocobalamin for Vasodilatory Hypotension in Shock: A Systematic Review With Meta-Analysis for Comparison to Methylene Blue.
Brokmeier HM, Seelhammer TG, Nei SD, et al. · J Cardiothorac Vasc Anesth 2023 · Meta-Analysis, Systematic Review
- Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials.
Kotani Y, Belletti A, D'Amico F, et al. · Crit Care 2024 · Meta-Analysis, Systematic Review
- ADJUNCTIVE VASOPRESSORS AND SHORT-TERM MORTALITY IN ADULTS WITH SEPTIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Bauer SR, Wieruszewski PM, Bissell Turpin BD, et al. · Shock 2025 · Systematic Review, Meta-Analysis
- High-Dose IV Hydroxocobalamin (Vitamin B12) in Septic Shock: A Double-Blind, Allocation-Concealed, Placebo-Controlled Single-Center Pilot Randomized Controlled Trial (The Intravenous Hydroxocobalamin in Septic Shock Trial).
Patel JJ, Willoughby R, Peterson J, et al. · Chest 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- Vasoplegic syndrome after cardiovascular surgery: A review of pathophysiology and outcome-oriented therapeutic management.
Datt V, Wadhhwa R, Sharma V, et al. · J Card Surg 2021 · Systematic Review
- Hydroxocobalamin analysis and pharmacokinetics.
Osterich JD, Hall AH · J Toxicol Clin Toxicol 1997 · Clinical Trial, Letter
Sponsor: Btg Intl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.